Blog

GB Group (LSE:GBG) reported full-year 2026 results in line with market expectations, posting revenue of £285 million, up 3.2% at constant currency, alongside adjusted operating profit of approximately £67.5 million, equating to a strong margin of 23.7%. Growth across its core Identity and Location divisions accelerated to 6% in the second half, supported by improved trading in the Americas and solid execution across EMEA.

The company pointed to strong early traction for its GBG Go adaptive identity platform, launched in April 2025, which has already secured 90 customer wins and built a pipeline exceeding 225 opportunities. This momentum highlights the platform’s scalability and cross-selling potential. GB Group also emphasised its disciplined capital strategy, returning value to shareholders through an £11 million dividend and £45 million in share buybacks, while strengthening its financial position with a new £175 million revolving credit facility extending to at least 2030. The group’s transition from AIM to the Main Market further supports its ambition for sustained mid-single-digit growth and enhanced investor appeal.

Strategically, the company continued to streamline operations toward a unified global model and completed its first bolt-on acquisition since 2022. Management expressed confidence that second-half momentum will carry into FY27, underpinning expectations for mid-single-digit revenue growth, alongside further initiatives aimed at accelerating expansion and reinforcing its global presence.

GB Group’s outlook is supported by solid financial delivery and proactive corporate actions that enhance shareholder returns. However, relatively high valuation multiples and mixed technical signals suggest some caution. While strategic progress and improving fundamentals provide a positive backdrop, challenges in certain segments and a premium P/E ratio may limit near-term upside.

More about GB Group plc

GB Group plc is a global provider of identity verification and location intelligence solutions, enabling businesses to confirm customer identities and addresses in digital environments. Serving over 20,000 clients worldwide, the company’s technology helps combat digital fraud, support compliance, and drive growth. Headquartered in the UK and listed on the London Stock Exchange as part of the FTSE 250, GB Group combines proprietary technology with extensive global data assets built over more than three decades.

hVIVO (LSE:HVO) has been awarded a contract by ILiAD Biotechnologies to conduct what is set to be the world’s first pivotal Phase III human challenge study for a whooping cough vaccine. The trial will evaluate ILiAD’s intranasal candidate, BPZE1, against the current Tdap vaccine standard. Expected to enrol more than 500 participants through FluCamp, the study will be the largest human challenge trial ever undertaken by hVIVO and will be supported by its specialist bacterial laboratory in Canary Wharf.

The multi-year agreement is anticipated to begin contributing revenue in the first half of 2026, with the majority of income recognised across 2026 and 2027. This contract is expected to provide a meaningful uplift to both near- and medium-term revenues. Management noted that the project highlights increasing regulatory acceptance of human challenge trials as a faster pathway to generating pivotal efficacy data, potentially reinforcing hVIVO’s competitive position while accelerating vaccine development for diseases with unpredictable transmission patterns, such as whooping cough.

Despite this significant contract win, the company’s broader outlook remains constrained by ongoing losses, substantial cash burn, and concerns around liquidity and forward visibility, as flagged in recent earnings commentary. Technical indicators point to a supportive upward trend, although overbought signals suggest some caution in the near term. Valuation continues to be pressured by negative earnings and the suspension of dividend payments.

More about hVIVO plc

hVIVO plc is a specialist clinical development company and a global leader in human challenge trials, partnering with seven of the world’s ten largest biopharmaceutical firms. The group provides a full-service platform spanning early-stage strategy through to Phase II trials, supported by its own clinical facilities, laboratories, and its FluCamp volunteer recruitment arm operating across the UK and Germany.

Bunzl (LSE:BNZL) reported a steady performance in the first quarter of 2026, with group revenue rising 1.5% at constant exchange rates and underlying revenue increasing by 2.0%. Growth was supported by higher volumes and pricing adjustments linked to tariffs, although this was partly offset by a lower number of trading days during the period. North America delivered slightly stronger underlying growth than the group average, while acquisitions contributed a small uplift. Adjusted operating profit remained in line with expectations for a more stable trading year.

Despite a backdrop of heightened macroeconomic and geopolitical uncertainty, the company reaffirmed its full-year 2026 guidance. Bunzl continues to expect moderate revenue growth at constant exchange rates, alongside a modest decline in operating margin compared with the previous year. Management described 2026 as a transitional year laying the groundwork for future profit expansion and pointed to a robust pipeline of acquisition opportunities, highlighting ongoing consolidation potential and long-term value creation prospects.

The company’s outlook is underpinned by solid financial fundamentals, particularly strong free cash flow generation, though this is balanced against leverage and some recent pressure on profitability and margins. Technical indicators remain supportive, with positive momentum in the share price, while valuation appears reasonable given a mid-teens P/E multiple and an approximate 3.3% dividend yield. However, management commentary reflects a degree of caution, citing expectations for slightly lower margins and continued regional and execution challenges.

More about Bunzl plc

Bunzl plc is a global distribution and services group specialising in non-food consumables. Its product range includes packaging, cleaning and hygiene supplies, as well as safety and healthcare products. The company serves business customers across sectors such as grocery, foodservice, healthcare, and industry, with a particularly strong footprint in North America alongside operations in other international markets.

MTI Wireless Edge (LSE:MWE) has announced two new defence-related contracts within its antenna division, together valued at approximately $1 million. The first order, worth $0.7 million, comes from an existing European defence customer and is scheduled for delivery within five months. The second contract, awarded by a domestic defence company, will be fulfilled over a two-year period. These agreements add to the company’s military antenna backlog and strengthen ties with both international and local defence clients.

Chief executive Moni Borovitz highlighted that the new contracts cap a strong April for the group, during which more than $9 million in defence orders have been secured. This momentum reflects sustained demand for MTI’s defence solutions, while also signalling broader opportunities across its wider operations. The expanding order book enhances revenue visibility within the defence segment and reinforces the company’s role as a supplier of RF and antenna technologies to the global defence communications market.

MTI’s outlook is supported by solid financial fundamentals, including low leverage and consistent profitability, alongside an attractive valuation with a relatively low P/E ratio and dependable dividend yield. However, this is partly offset by mixed technical signals, with some short-term weakness despite a supportive longer-term trend.

More about MTI Wireless Edge

MTI Wireless Edge is an Israel-based technology group focused on radio frequency and communication solutions across multiple divisions, including antennas, water management, and consulting services. Its antenna business develops advanced systems for both military and commercial applications, while its Mottech division delivers irrigation control solutions and MTI Summit provides RF, microwave, and defence engineering services. Serving global markets—from telecommunications and public safety to agriculture and defence—the group offers both standard and customised solutions aimed at high-reliability connectivity and monitoring.

Creo Medical (LSE:CREO) reported a strong opening to 2026, with first-quarter revenue increasing by around 60% year on year, reaching the upper end of management expectations. The performance supports its full-year guidance of 40% to 60% revenue growth, driven by continued commercial traction and growing clinical validation of its technology. At the same time, the company has agreed to divest and outsource its manufacturing operations, a move expected to reduce underlying operating costs by approximately 15% on an annualised basis compared with 2025, while enhancing scalability and efficiency.

The group is set to release its full-year 2025 results in May, which should provide further clarity on how accelerating revenue growth and cost-saving initiatives are influencing margins and cash consumption. The combination of strong top-line expansion and structural cost improvements is seen as a positive step in strengthening Creo’s position within the minimally invasive endoscopy market, and may offer investors greater confidence in its path toward sustainable profitability.

Despite this progress, the company’s broader outlook remains constrained by its financial profile, including ongoing losses and continued cash burn. While technical indicators show a supportive trend and positive momentum signals, an elevated RSI suggests the stock may be overbought in the near term. Valuation impact is neutral, as no P/E ratio or dividend yield has been disclosed.

More about Creo Medical

Creo Medical Group is a UK-listed medical technology company focused on minimally invasive surgical endoscopy solutions for pre-cancerous and cancerous conditions. Its portfolio includes advanced electrosurgical systems such as the CROMA platform, powered by Kamaptive adaptive energy technology, which aims to provide clinicians with more precise, flexible, and less invasive treatment options while improving patient outcomes and reducing procedural costs.

Croda International (LSE:CRDA) reported first-quarter 2026 sales of £431 million, representing a 1% increase at constant currency and broadly meeting expectations despite a tough comparison with the prior year. Growth across its Consumer Care division—particularly in Beauty Actives, fragrances and flavours, and home care—helped offset weaker performance in Life Sciences, where Crop Protection revenues declined by 8% at constant currency. Industrial Specialties also experienced slight pressure on volumes during the period.

From a regional perspective, Latin America delivered the strongest performance, supported by steady agricultural demand and robust Consumer Care activity. North America, however, lagged as crop protection markets normalised, compounded by weather-related disruption and softer consumer demand. The company noted that ongoing tensions in the Middle East have not materially affected operations to date. Management reiterated its full-year 2026 guidance and confirmed that its transformation programme remains on track to deliver margin expansion and improved returns, although currency movements are expected to reduce reported operating profit by approximately £4 million.

Croda’s overall outlook reflects a balance between stable financial fundamentals—such as manageable leverage and positive cash generation—and favourable technical momentum, against the backdrop of a relatively high valuation multiple. Execution risks remain, highlighted by exceptional charges and uneven performance across segments, even as guidance improves and transformation initiatives progress.

More about Croda International

Croda International is a UK-based specialty chemicals company providing innovative ingredients and technologies across consumer care, life sciences, and industrial markets. Its offerings include beauty actives, personal and home care ingredients, fragrances and flavours, as well as solutions for pharmaceuticals, crop protection, and seed enhancement, serving a global customer base.

Ferrexpo (LSE:FXPO) is seeking to raise at least $100 million in new equity to stabilise its finances and sustain operations, which have been heavily impacted by the ongoing war in Ukraine, repeated attacks on energy infrastructure, and the suspension of VAT refunds tied to its links with sanctioned beneficiary Kostiantyn Zhevago. The company has recently sold a transhipping vessel for $7.7 million as part of its efforts to boost liquidity, but has warned that failure to complete the proposed capital raise by 30 April 2026 could lead to a suspension of its shares and prevent it from preparing its 2025 accounts on a going concern basis.

The group’s cash reserves have fallen to around $20 million, with management indicating that available funds—including proceeds from the vessel sale—are expected to last only until late August 2026 under current operating conditions. The planned equity placing, targeting both existing and new institutional investors, remains subject to approvals from the board, shareholders, and the market, as well as backing from major shareholder Fevamotinico. Ferrexpo has described the fundraising as its only realistic short-term option to maintain reduced production levels, safeguard jobs and community contributions, and potentially restore operations to more sustainable levels if successfully executed.

The company’s outlook continues to be shaped by difficult financial conditions, including declining revenues and profitability. While technical indicators suggest relatively strong market momentum, valuation remains under pressure due to negative earnings. Recent corporate developments underscore both the operational challenges facing the business and its efforts to navigate a highly complex environment while maintaining responsible operations.

More about Ferrexpo

Ferrexpo plc is a London-listed iron ore producer focused on supplying high-quality pellets and concentrates to global steelmakers, particularly in Asia and China. Its core mining and processing operations are based in Ukraine, with exports reliant on Black Sea logistics, leaving the company exposed to ongoing geopolitical, infrastructure, and energy-related risks in the region.

Senior plc (LSE:SNR), the FTSE 250 engineering group, has upgraded its expectations for full-year 2026 following a solid first-quarter performance, underpinned by strength in its Aerospace division. The company, which supplies high-technology components and systems to global aerospace and defence, land vehicle, and energy OEMs, continues to position itself as a key player in supporting a more sustainable industrial future.

For the first quarter, revenue increased by 2.5% year on year at constant currency. Growth was led by Aerospace, where sales climbed 9.7% on the back of strong demand across both civil aviation and defence markets. In contrast, the Flexonics division saw revenue decline by 6.2%, reflecting weaker petrochemical activity, although performance still exceeded expectations due to solid demand from land vehicle customers.

Buoyed by this start to the year, management now anticipates that full-year 2026 results will come in comfortably ahead of earlier forecasts, highlighting improving momentum across both business segments. The company is scheduled to release its interim results for the six months to 30 June 2026 on 3 August, with investor attention likely centred on the durability of aerospace demand and the pace of recovery in Flexonics following last year’s peak in petrochemical-related projects.

Senior’s outlook is supported by steady financial progress and a positive earnings trajectory, including margin expansion, strong cash generation, and ongoing deleveraging. While technical indicators remain favourable, they appear somewhat stretched, and valuation continues to weigh on the investment case, with a relatively high P/E ratio and modest yield.

More about Senior plc

Senior plc is a UK-listed international engineering and manufacturing group and a constituent of the FTSE 250. It specialises in the design and production of advanced components and systems for major OEMs across aerospace and defence, land vehicles, and power and energy markets. Operating in 10 countries, the company is focused on delivering technologies that support the transition to a more sustainable global economy.

Alien Metals (LSE:UFO) is increasing its exposure to high-grade silver through its 30% interest in the Elizabeth Hill Silver Project in Western Australia’s West Pilbara, alongside an 8.7% stake in joint venture partner West Coast Silver. While the company’s primary focus remains its Hancock iron ore development and broader Pilbara assets, the silver project is emerging as an additional value driver within its portfolio.

West Coast Silver has announced a maiden JORC-compliant mineral resource estimate at Elizabeth Hill of 2.79 million ounces of silver at an average grade of 617 g/t. The estimate includes both Indicated and Inferred categories above a 20 g/t cut-off grade. Located on an existing mining lease and still open along strike and at depth, the project ranks among the highest-grade silver deposits in Australia and offers Alien Metals meaningful exposure to future exploration upside, development potential, and economic assessment work.

Preliminary pit optimisation studies indicate viable prospects for eventual extraction through a relatively compact open-pit operation, capturing the majority of known mineralisation, including previously mined underground zones. With a large portion of the resource still classified as Inferred and further drilling planned across the wider tenement package, the initial estimate is viewed as a starting point that could materially expand over time and strengthen Alien’s long-term silver exposure.

From a financial standpoint, the company continues to face challenges, including no current revenue, ongoing losses, and negative free cash flow, although recent trends show some improvement in losses and cash burn alongside low debt levels. Market technicals appear more supportive, with the share price trading above key moving averages and a positive MACD signal, while valuation remains constrained by its loss-making position and absence of dividends.

More about Alien Metals Ltd

Alien Metals Ltd is an AIM-listed exploration and development company focused on advancing mining projects through technical progress and strategic partnerships. Its flagship asset is the 90%-owned Hancock Iron Ore Project in Western Australia’s Pilbara region, supported by a broader portfolio that includes iron ore, platinum group metals, and precious metal interests such as Munni Munni and Elizabeth Hill.